Literature DB >> 26376163

Specificity of vascular endothelial growth factor treatment for radiation necrosis.

Carlos J Perez-Torres1, Liya Yuan2, Robert E Schmidt3, Keith M Rich4, Robert E Drzymala4, Dennis E Hallahan5, Joseph J H Ackerman6, Joel R Garbow7.   

Abstract

Recently, radiation induced necrosis in the brain has been treated using bevacizumab, an anti-VEGF antibody. We validated the VEGF specificity by comparing the therapeutic efficacy of anti-VEGF with non-specific isotype control antibody. Additionally, we found that VEGF over-expression and RN developed simultaneously, which precludes preventative anti-VEGF treatment.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Magnetic resonance imaging; Radiation necrosis; Vascular endothelial growth factor

Mesh：

Substances：

Year:  2015        PMID： 26376163      PMCID： PMC4854530          DOI： 10.1016/j.radonc.2015.09.004

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  18 in total

1.  An analysis of radiation necrosis of the central nervous system treated with bevacizumab.

Authors:  Karen Tye; Herbert H Engelhard; Konstantin V Slavin; M Kelly Nicholas; Steven J Chmura; Young Kwok; Dominic S Ho; Ralph R Weichselbaum; Matthew Koshy
Journal:  J Neurooncol       Date:  2014-02-07       Impact factor: 4.130

2.  Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

Authors:  Wei-Ching Liang; Xiumin Wu; Franklin V Peale; Chingwei V Lee; Y Gloria Meng; Johnny Gutierrez; Ling Fu; Ajay K Malik; Hans-Peter Gerber; Napoleone Ferrara; Germaine Fuh
Journal:  J Biol Chem       Date:  2005-11-07       Impact factor: 5.157

3.  Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.

Authors:  Victor A Levin; Luc Bidaut; Ping Hou; Ashok J Kumar; Jeffrey S Wefel; B Nebiyou Bekele; Jai Grewal; Sujit Prabhu; Monica Loghin; Mark R Gilbert; Edward F Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-01       Impact factor: 7.038

4.  The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles.

Authors:  Naosuke Nonoguchi; Shin-Ichi Miyatake; Motoi Fukumoto; Motomasa Furuse; Ryo Hiramatsu; Shinji Kawabata; Toshihiko Kuroiwa; Motomu Tsuji; Manabu Fukumoto; Koji Ono
Journal:  J Neurooncol       Date:  2011-06-18       Impact factor: 4.130

5.  Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.

Authors:  Douglas E Ney; Julie A Carlson; Denise M Damek; Laurie E Gaspar; Brian D Kavanagh; B K Kleinschmidt-DeMasters; Allen E Waziri; Kevin O Lillehei; Krishna Reddy; Changhu Chen
Journal:  J Neurooncol       Date:  2014-12-19       Impact factor: 4.130

6.  Effect of bevacizumab on radiation necrosis of the brain.

Authors:  Javier Gonzalez; Ashok J Kumar; Charles A Conrad; Victor A Levin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-02-01       Impact factor: 7.038

Review 7.  Radiation necrosis: relevance with respect to treatment of primary and secondary brain tumors.

Authors:  James Fink; Donald Born; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

8.  A GSK-3β inhibitor protects against radiation necrosis in mouse brain.

Authors:  Xiaoyu Jiang; Carlos J Perez-Torres; Dinesh Thotala; John A Engelbach; Liya Yuan; Jeremy Cates; Feng Gao; Robert E Drzymala; Keith M Rich; Robert E Schmidt; Joseph J H Ackerman; Dennis E Hallahan; Joel R Garbow
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-15       Impact factor: 7.038

9.  Toward distinguishing recurrent tumor from radiation necrosis: DWI and MTC in a Gamma Knife--irradiated mouse glioma model.

Authors:  Carlos J Perez-Torres; John A Engelbach; Jeremy Cates; Dinesh Thotala; Liya Yuan; Robert E Schmidt; Keith M Rich; Robert E Drzymala; Joseph J H Ackerman; Joel R Garbow
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-08-04       Impact factor: 7.038

10.  Anti-VEGF antibodies mitigate the development of radiation necrosis in mouse brain.

Authors:  Xiaoyu Jiang; John A Engelbach; Liya Yuan; Jeremy Cates; Feng Gao; Robert E Drzymala; Dennis E Hallahan; Keith M Rich; Robert E Schmidt; Joseph J H Ackerman; Joel R Garbow
Journal:  Clin Cancer Res       Date:  2014-03-19       Impact factor: 12.531
View more
  9 in total

1.  Preclinical MRI: Studies of the irradiated brain.

Authors:  Joel R Garbow; Christina I Tsien; Scott C Beeman
Journal:  J Magn Reson       Date:  2018-04-26       Impact factor: 2.229

2.  Can anti-vascular endothelial growth factor antibody reverse radiation necrosis? A preclinical investigation.

Authors:  Chong Duan; Carlos J Perez-Torres; Liya Yuan; John A Engelbach; Scott C Beeman; Christina I Tsien; Keith M Rich; Robert E Schmidt; Joseph J H Ackerman; Joel R Garbow
Journal:  J Neurooncol       Date:  2017-04-19       Impact factor: 4.130

3.  Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.

Authors:  Oliver Schnell; Jun Thorsteinsdottir; Daniel Felix Fleischmann; Markus Lenski; Wolfgang Abenhardt; Armin Giese; Jörg-Christian Tonn; Claus Belka; Friedrich Wilhelm Kreth; Maximilian Niyazi
Journal:  J Neurooncol       Date:  2016-09-06       Impact factor: 4.130

4.  Distinguishing Tumor Admixed in a Radiation Necrosis (RN) Background: 1H and 2H MR With a Novel Mouse Brain-Tumor/RN Model.

Authors:  Xia Ge; Kyu-Ho Song; John A Engelbach; Liya Yuan; Feng Gao; Sonika Dahiya; Keith M Rich; Joseph J H Ackerman; Joel R Garbow
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

5.  Inhibitors of HIF-1α and CXCR4 Mitigate the Development of Radiation Necrosis in Mouse Brain.

Authors:  Ruimeng Yang; Chong Duan; Liya Yuan; John A Engelbach; Christina I Tsien; Scott C Beeman; Carlos J Perez-Torres; Xia Ge; Keith M Rich; Joseph J H Ackerman; Joel R Garbow
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-12-21       Impact factor: 7.038

Review 6.  Brain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer Patients.

Authors:  Gokoulakrichenane Loganadane; Frédéric Dhermain; Guillaume Louvel; Paul Kauv; Eric Deutsch; Cécile Le Péchoux; Antonin Levy
Journal:  Front Oncol       Date:  2018-09-05       Impact factor: 6.244

7.  Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas - A Pilot Study.

Authors:  Hiroyuki Shiba; Koji Takeuchi; Ryo Hiramatsu; Motomasa Furuse; Naosuke Nonoguchi; Shinji Kawabata; Toshihiko Kuroiwa; Natsuko Kondo; Yoshinori Sakurai; Minoru Suzuki; Koji Ono; Shiro Oue; Eiichi Ishikawa; Hiroyuki Michiue; Shin-Ichi Miyatake
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-11-21       Impact factor: 1.742

8.  Minimal difference between fractionated and single-fraction exposure in a murine model of radiation necrosis.

Authors:  Andrew J Boria; Carlos J Perez-Torres
Journal:  Radiat Oncol       Date:  2019-08-13       Impact factor: 3.481

9.  Irradiation-Modulated Murine Brain Microenvironment Enhances GL261-Tumor Growth and Inhibits Anti-PD-L1 Immunotherapy.

Authors:  Joel R Garbow; Tanner M Johanns; Xia Ge; John A Engelbach; Liya Yuan; Sonika Dahiya; Christina I Tsien; Feng Gao; Keith M Rich; Joseph J H Ackerman
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.